Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Wagner

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
Journal of Clinical Pharmacology|June 4, 2009
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's diseaseCarol Addy, Chris Assaid, David Hreniuk, et al.
Seminars in Oncology|August 27, 2013
Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?Ubaldo E Martinez-Outschoorn, Diana Whitaker-Menezes, Matias Valsecchi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2011
Umbilical cord blood transplantation for children with thalassemia and sickle cell diseaseAnnalisa Ruggeri, Mary Eapen, Andromachi Scaravadou, et al.
Transplantation and Cellular Therapy|April 29, 2023
Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 SubstudyPaul Szabolcs, Roei D Mazor, Dima Yackoubov, et al.
Blood Advances|September 28, 2021
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantationJulie Kanter, Robert I Liem, Françoise Bernaudin, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/MethotrexateNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Genes & Development|July 11, 2015
H3K36 methylation promotes longevity by enhancing transcriptional fidelityPayel Sen, Weiwei Dang, Greg Donahue, et al.
Journal of Clinical Pharmacology|May 30, 2008
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteersCarol Addy, Paul Rothenberg, Susie Li, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 5, 2010
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasErica D Warlick, Marcie Tomblyn, Qing Cao, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|February 9, 2013
Clinical outcomes of children receiving intensive cardiopulmonary support during hematopoietic stem cell transplantChristine N Duncan, Leslie E Lehmann, Ira M Cheifetz, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
Journal of Clinical Pharmacology|June 4, 2009
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's diseaseCarol Addy, Chris Assaid, David Hreniuk, et al.
Seminars in Oncology|August 27, 2013
Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?Ubaldo E Martinez-Outschoorn, Diana Whitaker-Menezes, Matias Valsecchi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2011
Umbilical cord blood transplantation for children with thalassemia and sickle cell diseaseAnnalisa Ruggeri, Mary Eapen, Andromachi Scaravadou, et al.
Transplantation and Cellular Therapy|April 29, 2023
Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 SubstudyPaul Szabolcs, Roei D Mazor, Dima Yackoubov, et al.
Blood Advances|September 28, 2021
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantationJulie Kanter, Robert I Liem, Françoise Bernaudin, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/MethotrexateNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Genes & Development|July 11, 2015
H3K36 methylation promotes longevity by enhancing transcriptional fidelityPayel Sen, Weiwei Dang, Greg Donahue, et al.
Journal of Clinical Pharmacology|May 30, 2008
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteersCarol Addy, Paul Rothenberg, Susie Li, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 5, 2010
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasErica D Warlick, Marcie Tomblyn, Qing Cao, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|February 9, 2013
Clinical outcomes of children receiving intensive cardiopulmonary support during hematopoietic stem cell transplantChristine N Duncan, Leslie E Lehmann, Ira M Cheifetz, et al.
Pageof 14